Uterine fibroids can be classified as noncancerous growths of the uterus that can happen during childbearing years. The disease is also known as leiomyomas or myomas. The disease is not known to be cancerous, and its growth has rarely caused cancer.
Market Synopsis
Uterine Fibroids, in this disease, look like seedlings in the beginning but then they turn into bulky masses that have the potential to distort and make uterus grow big. It is quite challenging to identify these fibroids as they can be undetectable. Such expansion of the uterus can touch the rib cage, and it can be sensed in the rapidly growing weight.
Symptoms of this disease are so benign that these fibroids often go unnoticed, however, this can be detected while undergoing pelvic exam or prenatal ultrasound. The US market for uterine fibroid is expected to gain substantial boost due to the growing awareness and high investment capacity, along with superior medical facilities. The hike in investment for the healthcare sector and better investment for research & development can inspire the global uterine fibroids market further.
Intended Audience
- Uterine Fibroid Devices and Drug Manufacturers
- Uterine Fibroid Devices and Drug Suppliers
- Private Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Medical Research Laboratories
Avail FREE Sample at: https://www.marketresearchfuture.com/sample_request/2394
Top Key Competitive Landscape:
The U.S. market for the uterine fibroid has several companies participating as they have realized the vast potential of the market. The growing number of cases are demanding for better medication or treatment procedures, which have led these companies into devising various plans that can solidify their market position and assist in having growth for the market as a whole. MRFR profiled a few to have a better grasp over the market. These companies are AstraZeneca (England), Cook Medical Inc. (US), Boston Scientific Corporation (US), GE Healthcare (U.K.), AbbVie Inc. (U.S.), Hologic (U.S.), and others.
Segmentation:
The U.S. Uterine Fibroid Market can be segmented by type, diagnosis, and treatment. Such a segmentation relies heavily on factorial analyses that bring out insights, which can be used in the future for a better market understanding.
By type, the U.S. Uterine Fibroid Market can be studied as Submucosal Fibroids, Intramural Fibroids, Subserosal Fibroids, and others. These three segments are witnessing a substantial growth due to various reasons owing to which the market is expanding accordingly.
By diagnosis, the U.S. Uterine Fibroid market can be segmented into Computed tomography (CT), Medical Resonance Imaging (MRI) scanners, Ultrasounds, and others. Better technological integration is expected to provide high traction to the global market.
Based on the treatment, the U.S. Uterine Fibroid market includes Magnetic Resonance Guided Focused Ultrasound, Uterine Fibroid Embolization, Endometrial Ablation, Myolysis, Hysterectomy, and Myomectomy.
LIST OF TABLE
TABLE 1 U.S. UTERINE FIBROID MARKET, BY TYPE, 2013-2022 (USD MILLION)
TABLE 2 U.S. UTERINE FIBROID MARKET, BY DIAGNOSIS, 2013-2022 (USD MILLION)
TABLE 3 U.S. UTERINE FIBROID MARKET, BY TREATMENT, 2013-2022 (USD MILLION)
TABLE 4 U.S. UTERINE FIBROID MARKET, BY TREATMENT TYPE, 2013-2022 (USD MILLION)
TABLE 5 PIPELINE PRODUCTS FOR UTERINE FIBROIDS
TABLE 6 ASTRAZENECA: KEY DEVELOPMENT
…To be Continued.
Browse Complete Premium Research Page along with Detailed TOC at: https://www.marketresearchfuture.com/reports/uterine-fibroid-market-2394
Market News
In September 2019, Abbvie filed for approval for their product Orilissa, a medicine for uterine fibroid. The company is banking on to gain from first-mover’s advantage. Myovant is also planning to launch Relugolix.
Regional Analysis:
A region-specific study of the U.S. Uterine Fibroid market covers mainly diverse states like Alabama, California, Arizona, Illinois, Massachusetts, Michigan, Nebraska, and others. The market in the region is finding moderate growth due to a high level of awareness, which influences women to have various preventive measures and timely treatment. The regional market is getting substantial backing from various market players who are getting involved in an intense competition to facilitate the growth of the market in the region. These players are launching strategic move to meet the growing demand for the market. The market is getting covered mostly by treatment with drug and surgery, however only surgery segment is also gaining prominence. However, the market may find a scope to rise by 18.96% CAGR during the forecast period from the pharmacotherapy segment. Some of the medicines now available in the market have received positive results from the clinical trial, which is why this segment is expected to gain more traction in the market in the coming years.
Ask for an Exclusive Discount at: https://www.marketresearchfuture.com/check-discount/2394
Key Finding
- The U.S. Uterine Fibroid market and is expected to reach USD 39,993.2 million by 2022.
- By Type, Intramural Fibroids holds the largest market share of U.S. uterine fibroid market and is expected to reach USD 14,972.5 million by 2022.
- By Treatment, hysterectomy holds the largest market share of U.S. uterine fibroid market and is expected to reach USD 8,042.3 million by 2022.
About Market Research Future:
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact
Market Research Future
+1 646 845 9312
Comments
Post a Comment